Zealand Pharma Expands Metabolic Ambitions With OTR Deal

Zealand Pharma and OTR Therapeutics strike a collaboration to develop oral metabolic drugs, widening the field beyond injectables

16 Dec 2025

On December 11th Zealand Pharma announced a deal that nudges it into unfamiliar territory. The Danish firm, long known for peptide-based medicines, struck a multi-program collaboration with OTR Therapeutics to develop new treatments for metabolic diseases, including obesity. The partnership reflects both ambition and caution in a crowded market.

The agreement pairs Zealand with OTR’s small-molecule platform, a step away from injectables that currently dominate metabolic care. OTR will handle discovery and preclinical work. Zealand will take charge once candidates reach the clinic, overseeing development, regulatory filings and global sales. Such a division of labour is common: early science on one side, late-stage muscle on the other.

The financial terms are generous but back-loaded. OTR will receive $20m upfront, rising to $30m if certain conditions are met. Milestones linked to development, regulation and commercial success could lift total payments to about $2.5bn, most of it dependent on sales. Zealand has also agreed to pay tiered single-digit royalties on any approved products.

Why bother, when injectable drugs are booming? Convenience is the lure. Pills are cheaper to make, easier to ship and often more appealing to patients. They might also widen access, an important consideration as payers push back against the high cost of obesity treatments. Yet oral small molecules have so far struggled to match the potency and durability of injections. Many have failed.

Executives insist this is an addition, not a change of course. Zealand will continue to back peptides, while selectively adding new technologies that could strengthen its pipeline over time. The company is not alone. Across the industry, firms are hedging their bets, testing multiple approaches in parallel rather than betting on a single winner.

As ever, the risks are large. Early-stage science often disappoints. Regulators may be cautious. Payers may balk. Still, the deal shows how competition in metabolic disease is reshaping strategy. In a field where no advantage lasts long, optionality has become a virtue.